

HCZEN-200 TABLETS

Hydroxychloroquine Sulphate I.P. 200 mg

"Trusted DMARD for Autoimmune & Inflammatory Disorders"

Marketed by: Human Orthocare

A Subsidiary of Human Biolife India Pvt. Ltd.

www.humanorthocare.com



Product Overview

Composition (per tablet):

- ① Hydroxychloroquine Sulphate I.P. – 200 mg

Key Features:

- Widely used **antimalarial & immunomodulatory agent**
- Acts as a **DMARD** in autoimmune & rheumatologic conditions
- Reduces inflammation & disease activity
- Improves long-term prognosis in chronic autoimmune disorders

Hczen-200 represents a cornerstone therapy in the management of autoimmune conditions, offering patients a well-established treatment option with proven efficacy.



Mechanism of Action

Hydroxychloroquine:

1

Lysosomal pH Modulation

Increases lysosomal pH in antigen-presenting cells → decreases immune activation

2

Toll-like Receptor Interference

Interferes with toll-like receptor signalling → reduces inflammatory cytokine release

3

Autoantibody Inhibition

Inhibits autoantibody-mediated responses



Result → Suppresses disease activity & prevents progression in autoimmune disorders

Indications

Hczen-200 Tablets are recommended for:

Rheumatoid Arthritis

(RA)

Systemic Lupus Erythematosus

(SLE)

Discoid Lupus Erythematosus

Sjögren's Syndrome

Malaria

(treatment & prophylaxis, as per guidelines)



Clinical Advantages

Key Benefits of Hczen-200:



Disease-Modifying Action

Slows progression of RA & SLE, providing long-term joint protection and organ preservation.



GI & Hepatic Safety

Fewer GI & hepatic side effects compared to methotrexate, ensuring better tolerance.



Symptom Relief

Reduces pain, swelling & joint damage, improving patient quality of life significantly.



Convenient Dosing

Oral convenient once/twice daily dosing improves patient compliance and treatment outcomes.



Superior Safety Profile

Safer long-term tolerability vs other DMARDs with fewer systemic complications.

Comparison with Other DMARDs

Comprehensive comparison of key treatment parameters:

Parameter	Hczen-200 (HCQ)	Methotrexate	Leflunomide
Onset of Action	⚠️ Slow (6–12 wks)	✅ Moderate	✅ Moderate
Safety Profile	✅ Safer	⚠️ Hepatic, marrow toxicity	⚠️ Hepatic
Eye Monitoring	⚠️ Needed (Retinopathy risk)	❌ Not required	❌ Not required
Long-Term Use	✅ Safe	⚠️ Limited	⚠️ Limited

Dosage & Administration

1

Standard Dosage

Usual: 200–400 mg daily (as single or divided dose)

Taken with food to minimise GI upset

2


Special Populations

⚠ Adjust dose in renal/hepatic impairment

3

Monitoring Requirements

⚠ Baseline & annual ophthalmic checkup recommended



Proper dosing and monitoring ensure optimal therapeutic outcomes whilst minimising potential risks.



Safety & Tolerability

Possible Side Effects:

- GI upset (nausea, diarrhoea)
- Headache, dizziness
- Retinopathy (rare, dose & duration dependent)

Contraindications:

Pre-existing retinopathy

Hypersensitivity to hydroxychloroquine or 4-aminoquinolines

Children (unsupervised use, due to toxicity risk)



Why Prescribe Hczen-200?

Doctor's Choice For:



Trusted DMARD

For RA & SLE management with proven clinical efficacy



Superior Safety

Safer long-term profile vs methotrexate & leflunomide



Disease Control

Effective in reducing disease flares & joint damage



Patient Compliance

Convenient oral therapy → better compliance



Quality Assurance

Backed by Human Orthocare quality standards



**Human
Ortho Care**

A SUBSIDIARY OF HUMAN BIOLIFE INDIA PVT. LTD.

Contact Us

Step into care that moves you forward.

Use with clinical discretion, especially in high-risk orthopedic conditions.

HumAn Orthocare – A Subsidiary of Human Biolife India Pvt. Ltd.

For medical queries or collaboration:



www.humanorthocare.com